Annuncio pubblicitario
I mercati dell'Italia hanno chiuso

  • FTSE MIB

    34.727,40
    +318,06 (+0,92%)
     

  • Dow Jones

    42.313,00
    +137,89 (+0,33%)
     

  • Nasdaq

    18.119,59
    -70,70 (-0,39%)
     

  • Nikkei 225

    39.829,56
    +903,93 (+2,32%)
     

  • Petrolio

    68,64
    +0,97 (+1,43%)
     

  • Bitcoin EUR

    58.957,28
    +777,07 (+1,34%)
     

  • XRP EUR

    0,53
    -0,00 (-0,68%)
     

  • Oro

    2.680,80
    -14,10 (-0,52%)
     

  • EUR/USD

    1,1168
    -0,0011 (-0,10%)
     

  • S&P 500

    5.738,17
    -7,20 (-0,13%)
     

  • HANG SENG

    20.632,30
    +707,72 (+3,55%)
     

  • Euro Stoxx 50

    5.067,45
    +34,86 (+0,69%)
     

  • EUR/GBP

    0,8347
    +0,0015 (+0,18%)
     

  • EUR/CHF

    0,9379
    -0,0071 (-0,75%)
     

  • EUR/CAD

    1,5083
    +0,0034 (+0,22%)
     

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Dyne Therapeutics, Inc.
·1 minuto per la lettura
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc.

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference being held in New York on Monday, September 11, 2023 at 4:15 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203